BCDA (BioCardia, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BCDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Peter Altman | President and CEO | Buy | — | — |
| 2026-08-18 | Peter Altman | President and CEO | Buy | — | — |
| 2026-08-13 | Peter Altman | President and CEO | Buy | — | — |
| 2026-07-29 | Peter Altman | President and CEO | Buy | — | — |
| 2026-07-20 | Peter Altman | President and CEO | Buy | — | — |
| 2026-07-15 | Peter Altman | President and CEO | Buy | — | — |
| 2026-07-10 | Peter Altman | President and CEO | Buy | — | — |
| 2026-07-08 | Peter Altman | President and CEO | Buy | — | — |
| 2026-07-07 | David McClung | Chief Financial Officer | F | — | — |
| 2026-07-07 | JAY M MOYES | Director | A | — | — |
| 2026-07-07 | Andrew Scott Blank | Director | A | — | — |
| 2026-07-07 | Bill Facteau | Director | A | — | — |
| 2026-07-07 | Marvin Slosman | Director | A | — | — |
| 2026-07-07 | EDWARD M GILLIS | Senior Vice President, Devices | F | — | — |
| 2026-07-07 | Peter Altman | President and CEO | F | — | — |
| 2026-07-07 | Jim L. Allen | Director | A | — | — |
| 2026-07-07 | SIMON H STERTZER | Director | A | — | — |
| 2026-07-01 | Peter Altman | President and CEO | A | — | — |
| 2026-07-01 | EDWARD M GILLIS | Senior Vice President, Devices | A | — | — |
| 2026-07-01 | David McClung | Chief Financial Officer | A | — | — |
| 2026-06-24 | SIMON H STERTZER | Director | Buy | — | — |
| 2026-06-22 | Peter Altman | President and CEO | Buy | — | — |
| 2026-06-09 | Peter Altman | President and CEO | Buy | — | — |
| 2026-05-21 | Peter Altman | President and CEO | Buy | — | — |
| 2026-05-18 | Peter Altman | President and CEO | Buy | — | — |
| 2026-05-15 | Peter Altman | President and CEO | Buy | — | — |
| 2026-04-29 | Peter Altman | President and CEO | Buy | — | — |
| 2026-04-22 | Peter Altman | President and CEO | Buy | — | — |
| 2026-03-26 | Peter Altman | President and CEO | Buy | — | — |
| 2026-02-04 | Peter Altman | President and CEO | Buy | — | — |
| 2026-01-21 | Peter Altman | President and CEO | Buy | — | — |
| 2025-12-17 | Peter Altman | President and CEO | Buy | — | — |
| 2025-12-10 | Andrew Scott Blank | Director | A | — | — |
| 2025-12-10 | Jim L. Allen | Director | A | — | — |
| 2025-12-10 | Peter Altman | President and CEO | MIXED | — | — |
| 2025-12-10 | David McClung | Chief Financial Officer | MIXED | — | — |
| 2025-12-10 | Marvin Slosman | Director | A | — | — |
| 2025-12-10 | Bill Facteau | Director | A | — | — |
| 2025-12-10 | SIMON H STERTZER | Director | A | — | — |
| 2025-12-10 | EDWARD M GILLIS | Senior Vice President, Devices | MIXED | — | — |
| 2025-12-10 | JAY M MOYES | Director | A | — | — |
| 2025-09-23 | Andrew Scott Blank | Director | Buy | — | — |
| 2025-09-23 | Peter Altman | President and CEO | Buy | — | — |
| 2025-09-23 | SIMON H STERTZER | Director | Buy | — | — |
| 2025-08-25 | Peter Altman | President and CEO | Buy | — | — |
| 2025-08-13 | Peter Altman | President and CEO | Buy | — | — |
| 2025-08-12 | Peter Altman | President and CEO | Buy | — | — |
| 2025-08-11 | Peter Altman | President and CEO | Buy | — | — |
| 2025-07-02 | David McClung | Chief Financial Officer | Buy | — | — |
| 2025-07-02 | Peter Altman | President and CEO | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 718,392 | — |
| — | Director | 636,058 | — |
| — | President and CEO | 381,985 | — |
| — | Chief Financial Officer | 114,245 | — |
| — | Director | 109,667 | — |
| — | 10%+ Owner | 95,373 | — |
| — | Senior Vice President, Devices | 54,126 | — |
| — | Director | 16,268 | — |
| — | Director | 13,123 | — |
| — | Vice President of Quality | 5,982 | — |
| — | Director | 4,337 | — |
| — | Director | 1,651 | — |
| — | Director | 476 | — |
| — | Director | 291 | — |
| — | Interim CEO and Interim CFO | 187 | — |
| — | Director | 106 | — |
| — | Director | 56 | — |
| — | Director | 25 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCDA quote page; the site-wide leaderboard is on the insider transactions hub.